TICKERNERD
Menu
OGNOGNHealthcare · Drug Manufacturers - General

OGN Stock Forecast: Organon & Co. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$14
+0.07% on the day

The 5 Wall Street analysts covering Organon & Co. hold a median 12-month price target of $12 — -15.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 14 Sept 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$3.6B
Ticker Nerd rank
74 / 100
Median analyst target
$12
Analysts covering
5
Revenue$1.6B−2.3% y/y
Operating income$323.0M
Net income$108.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
−0.5%
YTD
+91.4%
1Y
+29.2%
From 52W high
−0.9%
From 52W low
+140.2%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organon & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Momentum
83
Issuance
80
Accruals
75
Quality
72
Volatility
47
Revisions
37
Growth
32
Size
28

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26OGNHigh $14Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
0 Buy4 Hold1 Sell
Low $8Median $12High $14

The green dot is the last close — the median target sits −15.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Apr 2026BNP ParibasDowngradeNeutral$12 → $14
28 Apr 2026Piper SandlerUpgradeNeutral$5.00 → $14
24 Feb 2026BarclaysMaintainsUnderweight—
9 Dec 2025BarclaysInitiatesUnderweight—
11 Nov 2025JP MorganMaintainsUnderweight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
15 May 2025Piper SandlerMaintainsOverweight—
5 May 2025Morgan StanleyMaintainsEqual-Weight—
9 Apr 2025Morgan StanleyMaintainsEqual-Weight—
14 Feb 2025BarclaysMaintainsOverweight—
14 Feb 2025Morgan StanleyMaintainsEqual-Weight—
6 Sept 2024JP MorganDowngradeUnderweight—
6 May 2024Goldman SachsMaintainsNeutral—
3 May 2024Goldman SachsMaintainsNeutral—
29 Apr 2024Piper SandlerMaintainsOverweight—
20 Feb 2024Goldman SachsMaintainsNeutral—
22 Nov 2023Piper SandlerMaintainsOverweight—
3 Nov 2023Goldman SachsDowngradeNeutral—
25 Oct 2023Piper SandlerMaintainsOverweight—
11 Oct 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Organon & Co. returned +29.2% against +17.0% for the S&P 500, dividends included.

OGN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26OGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.1%
Analysts raising
0
Analysts cutting
1
Fundamentals

Organon & Co. (OGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.5×

Cheaper than 42% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
7.0×

Cheaper than 49% of US stocks

Growth & margins
Revenue growth (YoY)
−2.3%

Higher than 24% of US stocks

Earnings growth (YoY)
−25.5%

Higher than 18% of US stocks

Gross margin
54.4%

Higher than 67% of US stocks

Operating margin
20.7%

Higher than 80% of US stocks

Net margin
3.4%

Higher than 56% of US stocks

Returns & dividend
Return on equity
24.0%

Higher than 84% of US stocks

Return on assets
5.7%

Higher than 80% of US stocks

Dividend yield
0.6%

Higher than 11% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Organon & Co. (OGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Organon & Co. has a market value of $3.6B and an enterprise value of $11.0B.

  • Revenue in the twelve months to 30 June 2026: $6.1B. The latest quarter shrank 2.3% year on year.

  • Net income over the same four quarters: $209.0M, a 3.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.77.

  • Free cash flow in the twelve months to 30 June 2026: $434.0M, after $170.0M of capital spending.

  • Organon & Co. spent $18.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 262.6M.

  • Trailing P/E: 17.5×; forward P/E: 3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.59%, paying out 10% of earnings.

  • Organon & Co. employs 10,000 people — $613K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

OGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
OGNOrganon & Co.$3.6B
74
BIIBBiogen, Inc.$31.9B
75
IDYAIDEAYA Biosciences, Inc.*$3.6B
80
ABCLAbCellera Biologics, Inc.*$3.6B
71
NHCNational HealthCare Corp.*$3.5B
67
VKTXViking Therapeutics, Inc.*$3.6B
28
PLSEPulse Biosciences, Inc.*$3.7B
42

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organon & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGN news & analysis

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Business Wire · 14 Sept 2026positive

Organon announced that the U.S. FDA has accepted for review its supplemental New Drug Application for MIUDELLA, a hormone-free intrauterine device. The application seeks to extend the approved duration of use in the U.S. from 3 years to 6 years.

Why it matters — An approved extension of MIUDELLA's use duration would strengthen the product's competitive position and long-term value for Organon's women's health portfolio.

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research · 8 Sept 2026neutral

Zacks.com users have recently been paying increased attention to Organon (OGN), prompting a review of the facts that could determine the stock's prospects. The article highlights growing investor interest in the company.

Why it matters — A rise in investor attention and scrutiny of Organon's prospects suggests that watchers should be aware of the factors driving current interest in the stock.

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

GlobeNewsWire · 27 Aug 2026neutral

Women's Health Collective Canada and the Partnership for Women's Health Research Canada, in partnership with GreenShield and supported by a charitable grant from Organon, launched the Can-RISE study—the first national investigator-led study of Canadian women's experiences of menopause and the menopausal transition.

Why it matters — Organon's charitable grant links the company to a landmark national menopause research initiative, underscoring its engagement in women's health research.

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Business Wire · 11 Aug 2026positive

Organon has opened the REMS certification program for MIUDELLA, its hormone-free copper IUD, allowing healthcare providers, settings, and pharmacies to begin certification ahead of the product's anticipated commercial launch.

Why it matters — The REMS program launch signals that MIUDELLA is moving closer to market availability, which could expand Organon's women's health product portfolio and revenue stream.

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research compared Organon's Q2 2026 revenue and EPS against Wall Street estimates and year-ago figures, noting that headline numbers don't tell the full story of the quarter's performance.

Why it matters — Investors tracking Organon would care about how key operational metrics stack up against analyst expectations and prior-year results for a clearer picture of business trends beyond just revenue and earnings.

FAQ

Frequently asked questions about OGN stock

What is the OGN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Organon & Co. have a median 12-month price target of $12, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OGN stock a buy right now?

Of the 5 analysts covering Organon & Co., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Organon & Co. 74 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGN?

As at 14 Sept 2026, Organon & Co. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will OGN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -15.8% from the last close, and Ticker Nerd's factor model ranks Organon & Co. 74 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OGN stock forecast for 2030?

No analyst covering Organon & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.

How has OGN stock performed over the past year?

Organon & Co. returned +29.2% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organon & Co. do?

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines.

What is the latest news on OGN?

The most recent item we track (Business Wire, 14 Sept 2026): "Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device". Organon announced that the U.S. FDA has accepted for review its supplemental New Drug Application for MIUDELLA, a hormone-free intrauterine device. The application seeks to extend the approved duration of use in the U.S. from 3 years to 6 years.

Company

About Organon & Co.

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.

CEO Mr. Kevin Ali · 10,000 employees · United States · https://www.organon.com